Levitra was the original U.S. trade name for vardenafil hydrochloride film-coated tablets prescribed for erectile dysfunction. Its historical brand labeling described on-demand PDE5-inhibitor treatment in several tablet strengths, but the original U.S. branded product presentations were later discontinued. The continued appearance of Levitra in search results should not be mistaken for proof of a current branded purchase option.
The active ingredient did not disappear with the brand. Separate FDA-approved generic vardenafil applications exist, and their labeling, dosage forms and market status must be checked independently. A pharmacist cannot infer current stock from a historical brand label or old NDC.
This page focuses on the Levitra brand’s lifecycle and how a patient can identify an appropriate current product through legitimate care. For the ingredient, read the vardenafil overview; for regulatory generic identity, see the generic guide. It is not a buy-Levitra page.
Levitra contained vardenafil hydrochloride and was labeled as a prescription treatment for erectile dysfunction. As with other PDE5 inhibitors, its effect required sexual stimulation and could not be described as creating an automatic or permanent erection.
The brand name helped distinguish its film-coated tablets from other ED ingredients, but it never removed the need to assess interactions, cardiovascular considerations or individual response. Historic product recognition is not clinical evidence that the brand would suit every patient.
U.S. Levitra labeling described film-coated tablets in 2.5, 5, 10 and 20 mg strengths. Those are historical product facts; they are not a menu for self-prescribing or a reliable indication of present-day pharmacy supply.
The vardenafil strengths catalog describes the modern regulatory distinction between labeled strengths and dispensable generic products. The 2.5 mg guide additionally addresses why the lowest historical brand strength deserves careful status checks.
These distinctions keep old marketing records from being interpreted as live pharmacy information. A search result can be accurate about a product’s history while still being unsuitable for a current purchasing decision.
Before accepting a prescription fill, ask a licensed pharmacist to identify the actual generic application, dosage form and stock.
| Question | Historical Levitra context | Current verification |
|---|---|---|
| Trade name | Levitra was the U.S. film-coated brand | Do not assume brand stock |
| Active ingredient | Vardenafil hydrochloride | Check the dispensed generic label |
| Strengths | 2.5, 5, 10 and 20 mg were labeled | Confirm exact approved generic strength |
| Dosage form | Film-coated oral tablets | Do not replace with ODT automatically |
| Marketing status | Original branded presentations discontinued | Verify current generic application and inventory |
| Purchase route | Historical brand record is not a seller | Require valid Rx and licensed pharmacy |
Discontinued marketing and withdrawal for safety or effectiveness are different regulatory concepts. In a 2019 Federal Register determination, FDA stated that Levitra 2.5 mg tablets were not withdrawn for reasons of safety or effectiveness. In a separate 2023 determination, FDA reached the same conclusion for the 5 mg, 10 mg and 20 mg strengths. Those decisions preserve the regulatory possibility of qualifying generic applications; they do not imply that Bayer still markets Levitra or that any particular generic strength can be obtained today.
The original branded strengths remain part of the historical discontinued-product context. A pharmacy must independently check current approved generic applications, exact labeled form and real inventory. The FDA determination is about the reason for the brand’s discontinuation, not a patient-level declaration that vardenafil has no important side effects or contraindications.
Staxyn was the historical orally disintegrating vardenafil brand, with a 10 mg ODT presentation, whereas Levitra was supplied as film-coated tablets. Staxyn produced different systemic exposure and was specifically described in labeling as not interchangeable with 10 mg Levitra tablets.
Brand names can be used loosely in old search pages, so verify the precise prescription form. The Staxyn page addresses the former brand, and the ODT page explains formulation details.
Generic film-coated vardenafil products can be approved by FDA under product-specific applications. Qualifying substitutions depend on the exact product, strength and therapeutic-equivalence evaluation—not simply on sharing vardenafil as an ingredient.
An independent generic approval should be confirmed against the relevant U.S. records. Pharmacies may use labelers or tablet imprints unfamiliar to patients who remember Levitra; the dispensing pharmacist can identify the new product.
Vardenafil can dangerously potentiate nitrates and riociguat. It also carries QT-prolongation precautions, including concerns with congenital QT prolongation and certain antiarrhythmic drugs. Generic products containing the same active ingredient require these interactions to be assessed rather than assuming the risk applied only to the old brand.
ED symptoms may coexist with cardiovascular or metabolic conditions. The need for assessment is not reduced because a familiar trade name appears in a search result. The interaction page gives the class-by-class context.
Images of historic boxes and package inserts can help identify past products but do not verify authenticity, expiration, approval or supply of an item advertised today. A seller displaying original brand artwork without a verifiable licensed pharmacy should be treated with caution.
For any modern prescription fill, confirm the product’s actual manufacturer or labeler, formulation, strength and pharmacist contact. Avoid overseas offers that imply historical Levitra branding constitutes authorization to sell a foreign medicine in the U.S.
Tell the clinician or pharmacist the original prescription strength, dosage form and any past adverse effects. Ask whether an approved generic film-coated vardenafil product is appropriate and whether it is available for lawful dispensing. The clinician makes any change in regimen.
If a patient has an old box or prescription, compare that information with the current product rather than independently converting to a different form. The prescription guide explains review and renewal steps.
First identify whether the interest is in the historical Levitra brand or the current vardenafil ingredient. Then obtain individualized medical review, verify the proposed U.S.-approved generic and ask a licensed pharmacy to confirm availability and the exact filled product.
For the end-to-end lawful pharmacy pathway, use buy vardenafil in the U.S.. For stock checks without unsupported guarantees, see the availability guide.
The original branded U.S. Levitra presentations were discontinued; current generic vardenafil products are a separate matter.
Levitra contained vardenafil hydrochloride, a prescription PDE5 inhibitor used for erectile dysfunction.
The original film-coated tablet labeling included 2.5, 5, 10 and 20 mg presentations.
FDA determined that the discontinued Levitra 2.5 mg strength (2019), and the 5, 10 and 20 mg strengths (2023), were not withdrawn for reasons of safety or effectiveness. Vardenafil still has significant labeled safety precautions.
An appropriately approved film-coated generic may be an option when permitted by the prescription and applicable substitution rules; confirm with the prescriber and pharmacist.
No. Staxyn was the 10 mg orally disintegrating formulation and was not interchangeable with a 10 mg film-coated Levitra tablet.
No. Historic brand names and approved-product records do not establish current shelf inventory.
Yes. FDA-approved vardenafil ED medicines require a valid prescription in the United States.